Muraki H, Tsutsui K, Sato K, Toyama O, Nakazawa M, Niizuma S
Radioisotopes. 1987 Jan;36(1):24-7. doi: 10.3769/radioisotopes.36.24.
We have reported fundamental studies on the TSH immunoradiometric assay, using TSH RIABEAD II kit (Dainabot). The sensitivity of the assay was 0.03 mu IU/ml and its C.V. was 27.2%. Intra- and inter-assay C.V. were less than 5%. Dilution test and recovery test were good. Serum TSH level was 0.3-4.0 mu IU/ml in normal subjects, less than 0.03 mu IU/ml in untreated Graves' disease and subacute thyroiditis. Therefore, it was found that the clear difference exist in serum TSH levels between normal subjects and patients with untreated Graves' disease. There was a well correlation on the serum TSH levels between this method and TSH radioimmunoassay kit (Amerlex TSH, r = 0.983). Especially, the measurement of serum TSH levels, using immunoradiometric assay kit, was useful for the diagnosis of patients with Graves' disease.
我们已经报道了使用TSH RIABEAD II试剂盒（日本第一制药）对促甲状腺激素免疫放射分析的基础研究。该分析方法的灵敏度为0.03微国际单位/毫升，变异系数为27.2%。批内和批间变异系数均小于5%。稀释试验和回收试验结果良好。正常受试者血清促甲状腺激素水平为0.3 - 4.0微国际单位/毫升，未经治疗的格雷夫斯病和亚急性甲状腺炎患者血清促甲状腺激素水平低于0.03微国际单位/毫升。因此，发现正常受试者与未经治疗的格雷夫斯病患者的血清促甲状腺激素水平存在明显差异。该方法与促甲状腺激素放射免疫分析试剂盒（Amerlex TSH）测得的血清促甲状腺激素水平之间具有良好的相关性（r = 0.983）。特别是，使用免疫放射分析试剂盒测定血清促甲状腺激素水平，对格雷夫斯病患者的诊断很有用。
